Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic assessments
NEW YORK–(BUSINESS WIRE)–Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear’s previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unprecedented real-world and real-time cardiometabolic diagnostic assessments to the pharmaceutical, medtech, biotech, contract-research-organization (CRO) and direct-to-consumer (DTC) research communities.
